Ahmed HAMDY,Wayne ROTHBAUM,Raquel IZUMI,Brian LANNUTTI,Todd COVEY,Roger ULRICH,Dave JOHNSON,Tjeerd BARF,Allard KAPTEIN
申请号：
US16388832
公开号：
US20190358235A1
申请日:
2019.04.18
申请国别(地区):
US
年份:
2019
代理人:
摘要：
In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-δ inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.
